AR082579A2 - Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad - Google Patents
Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidadInfo
- Publication number
- AR082579A2 AR082579A2 ARP110102851A ARP110102851A AR082579A2 AR 082579 A2 AR082579 A2 AR 082579A2 AR P110102851 A ARP110102851 A AR P110102851A AR P110102851 A ARP110102851 A AR P110102851A AR 082579 A2 AR082579 A2 AR 082579A2
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- oral administration
- variability
- reducing
- levels
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 abstract 5
- 239000004094 surface-active agent Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica espontáneamente dispersable para administración oral, la cual comprende N-benzoil-estaurosporina.Reivindicación 2: Una composición farmacéutica espontáneamente dispersable para administración oral, la cual comprende N-benzoil-estaurosporina en la forma de un precursor micelar. Reivindicación 3: Una composición farmacéutica espontáneamente dispersable para administración oral, la cual comprende: i) N-benzoil-estaurosporina, ii) un componente hidrofílico, y iii) un tensoactivo. Reivindicación 4: Una composición como se reclama en cualquiera de las reivindicaciones 1 a 3, la cual comprende un componente lipofílico. Reivindicación 17: Un método para incrementar los niveles de biodisponibilidad o para reducir la variabilidad de los niveles de biodisponibilidad de N-benzoil-estaurosporina, mediante la mezcla de N-benzoil-estaurosporina con un vehículo que comprende un componente hidrofílico, y un tensoactivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9903547.9A GB9903547D0 (en) | 1999-02-16 | 1999-02-16 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082579A2 true AR082579A2 (es) | 2012-12-19 |
Family
ID=10847896
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100627A AR022589A1 (es) | 1999-02-16 | 2000-02-14 | UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER |
| ARP110102851A AR082579A2 (es) | 1999-02-16 | 2011-08-05 | Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000100627A AR022589A1 (es) | 1999-02-16 | 2000-02-14 | UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20020061873A1 (es) |
| EP (1) | EP1152750B1 (es) |
| JP (2) | JP5057610B2 (es) |
| KR (2) | KR100880859B1 (es) |
| CN (1) | CN100367930C (es) |
| AR (2) | AR022589A1 (es) |
| AT (1) | ATE430554T1 (es) |
| AU (1) | AU765776B2 (es) |
| BR (1) | BRPI0008228B8 (es) |
| CA (1) | CA2362277C (es) |
| CL (1) | CL2009001682A1 (es) |
| CZ (1) | CZ303979B6 (es) |
| DE (1) | DE60042151D1 (es) |
| DK (1) | DK1152750T3 (es) |
| EC (1) | ECSP083351A (es) |
| ES (1) | ES2326783T3 (es) |
| GB (1) | GB9903547D0 (es) |
| HK (1) | HK1045807B (es) |
| HU (1) | HUP0105364A3 (es) |
| ID (1) | ID30504A (es) |
| IL (3) | IL144512A0 (es) |
| MY (1) | MY128362A (es) |
| NO (1) | NO331232B1 (es) |
| NZ (1) | NZ513529A (es) |
| PE (1) | PE20001499A1 (es) |
| PL (1) | PL198330B1 (es) |
| PT (1) | PT1152750E (es) |
| RU (1) | RU2266121C2 (es) |
| SI (1) | SI1152750T1 (es) |
| SK (1) | SK286967B6 (es) |
| TR (1) | TR200102385T2 (es) |
| TW (1) | TWI240636B (es) |
| WO (1) | WO2000048571A1 (es) |
| ZA (1) | ZA200106677B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6200968B1 (en) * | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
| US7795246B2 (en) | 1998-08-06 | 2010-09-14 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
| ES2261671T3 (es) * | 2001-03-26 | 2006-11-16 | Novartis Ag | Mezcla farmaceutica que incluye una estaurosporina poco soluble en agua, un surfactante y un polimero soluble en agua. |
| KR20080091866A (ko) | 2001-05-16 | 2008-10-14 | 노파르티스 아게 | Ν-｛5-[4-(4-메틸-피페라지노-메틸)-벤조일아미도]-2-메틸페닐｝-4-(3-피리딜)-2-피리미딘-아민 및 화학치료제를 포함하는 배합물 |
| CN101703509A (zh) | 2001-10-30 | 2010-05-12 | 诺瓦提斯公司 | 作为flt3受体酪氨酸激酶活性抑制剂的星形孢菌素衍生物 |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| CA2492989C (en) * | 2002-07-23 | 2012-11-20 | Novartis Ag | Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent |
| US7842791B2 (en) * | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| GB0419159D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
| US20100038816A1 (en) * | 2006-08-16 | 2010-02-18 | Novartis Ag | Method of making solid dispersions of highly crystalline therapeutic compounds |
| FR2918566B1 (fr) | 2007-07-11 | 2009-10-09 | Pierre Fabre Medicament Sa | Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine. |
| US20090155352A1 (en) * | 2007-11-20 | 2009-06-18 | Cephalon, Inc. | Microemulsion containing indolocarbazole compound and dosage forms containing the same |
| EP2229936B1 (en) * | 2009-03-09 | 2015-05-06 | PharmaSol GmbH | Nanonized testosterone formulations for improved bioavailability |
| WO2011000811A2 (en) * | 2009-06-30 | 2011-01-06 | Novartis Ag | Organic compounds |
| MX2012007229A (es) * | 2009-12-22 | 2012-07-30 | Leo Pharma As | Composicion cutanea que comprende analogo de vitamina d y mezcla de solvente y tensioactivos. |
| JO3337B1 (ar) * | 2010-12-13 | 2019-03-13 | Debiopharm Sa | تركيبات صيدلية تشمل أليسبوريفير |
| US9387446B2 (en) | 2011-09-22 | 2016-07-12 | Ariel-University Research And Development Company Ltd. | Emulsions and methods of making emulsions |
| RU2742650C2 (ru) * | 2015-12-09 | 2021-02-09 | Фосфейдженикс Лимитед | Фармацевтический состав |
| CN114712308A (zh) | 2015-12-09 | 2022-07-08 | 磷肌酸有限公司 | 药物制剂 |
| EP3558903B1 (en) | 2016-12-21 | 2024-07-03 | Avecho Biotechnology Limited | Process for phosphorylating a complex alcohol |
| US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| US4735939A (en) | 1987-02-27 | 1988-04-05 | The Dow Chemical Company | Insecticidal activity of staurosporine |
| US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| DE3824034C1 (es) * | 1988-07-15 | 1989-09-14 | Gustav 7290 Freudenstadt De Memminger | |
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| CA2108266C (en) | 1991-04-19 | 2003-06-03 | Albert J. Owen | Convertible microemulsion formulations |
| GB9113872D0 (en) | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| DK0589843T3 (da) * | 1992-09-25 | 2002-04-02 | Novartis Ag | Cyclosporinholdige farmaceutiske præparater |
| US6306421B1 (en) * | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5981568A (en) * | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| CH686761A5 (de) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| US5639474A (en) | 1993-07-01 | 1997-06-17 | Hanmi Pharm. Ind., Ltd. | Cyclosporin soft capsule composition |
| AU692506B2 (en) | 1993-11-17 | 1998-06-11 | Ibah, Inc. | Transparent liquid for encapsulated drug delivery |
| GB9325395D0 (en) | 1993-12-11 | 1994-02-16 | Ciba Geigy Ag | Compositions |
| WO1995022331A1 (en) | 1994-02-18 | 1995-08-24 | Cephalon, Inc. | Aqueous indolocarbazole solutions |
| WO1995032975A1 (en) * | 1994-06-01 | 1995-12-07 | Ciba-Geigy Ag | Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents |
| GB2308545B (en) | 1994-10-26 | 1999-06-02 | Novartis Ag | Pharmaceutical microemulsion preconcentrates |
| IL115742A (en) * | 1994-10-26 | 2000-06-01 | Novartis Ag | Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant |
| EP0711557A1 (de) * | 1994-11-09 | 1996-05-15 | Ciba-Geigy Ag | Pharmazeutische Formulierungsgrundlage |
| EP0733358A3 (de) * | 1995-03-21 | 1998-05-20 | Novartis AG | Intravenös applizierbare Nanosuspensionen |
| WO1998013032A1 (en) | 1996-09-27 | 1998-04-02 | Trega Biosciences, Inc. | Compositions of therapeutic agents suitable for oral administration |
| DE19641672A1 (de) | 1996-10-10 | 1998-04-16 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen |
| US5827522A (en) | 1996-10-30 | 1998-10-27 | Troy Corporation | Microemulsion and method |
| NZ314060A (en) | 1997-01-13 | 1997-08-22 | Bernard Charles Sherman | Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s) |
| AU737053B2 (en) * | 1997-01-30 | 2001-08-09 | Novartis Ag | Oil-free pharmaceutical compositions containing cyclosporin A |
| KR100509130B1 (ko) | 1997-07-29 | 2005-08-18 | 파마시아 앤드 업존 캄파니 엘엘씨 | 친지성 화합물의 자가유화 제제 |
| SK284511B6 (sk) | 1997-07-29 | 2005-05-05 | Pharmacia & Upjohn Company | Samoemulgujúce formulácie pre lipofilné zlúčeniny |
| US6346511B1 (en) | 1997-09-08 | 2002-02-12 | Panacea Biotec Limited | Pharmaceutical composition comprising cyclosporin |
| US6979456B1 (en) * | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
| GB9814527D0 (en) * | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| AR013276A1 (es) | 1998-07-31 | 2000-12-13 | Panacea Biotec Ltd | Composicion de ciclosporina transparente |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
-
1999
- 1999-02-16 GB GBGB9903547.9A patent/GB9903547D0/en not_active Ceased
-
2000
- 2000-02-14 PL PL350556A patent/PL198330B1/pl unknown
- 2000-02-14 JP JP2000599363A patent/JP5057610B2/ja not_active Expired - Fee Related
- 2000-02-14 PE PE2000000113A patent/PE20001499A1/es not_active Application Discontinuation
- 2000-02-14 AU AU31542/00A patent/AU765776B2/en not_active Expired
- 2000-02-14 WO PCT/EP2000/001196 patent/WO2000048571A1/en not_active Ceased
- 2000-02-14 BR BRPI0008228A patent/BRPI0008228B8/pt not_active IP Right Cessation
- 2000-02-14 DK DK00909165T patent/DK1152750T3/da active
- 2000-02-14 ID IDW00200101649A patent/ID30504A/id unknown
- 2000-02-14 AR ARP000100627A patent/AR022589A1/es not_active Application Discontinuation
- 2000-02-14 HK HK02106758.7A patent/HK1045807B/zh not_active IP Right Cessation
- 2000-02-14 AT AT00909165T patent/ATE430554T1/de active
- 2000-02-14 EP EP00909165A patent/EP1152750B1/en not_active Expired - Lifetime
- 2000-02-14 RU RU2001124597/15A patent/RU2266121C2/ru active
- 2000-02-14 KR KR1020017009391A patent/KR100880859B1/ko not_active Expired - Lifetime
- 2000-02-14 CZ CZ20012931A patent/CZ303979B6/cs not_active IP Right Cessation
- 2000-02-14 CN CNB008038244A patent/CN100367930C/zh not_active Expired - Lifetime
- 2000-02-14 CA CA2362277A patent/CA2362277C/en not_active Expired - Lifetime
- 2000-02-14 TR TR2001/02385T patent/TR200102385T2/xx unknown
- 2000-02-14 KR KR1020087015449A patent/KR20080064914A/ko not_active Withdrawn
- 2000-02-14 IL IL14451200A patent/IL144512A0/xx active IP Right Grant
- 2000-02-14 SK SK1172-2001A patent/SK286967B6/sk not_active IP Right Cessation
- 2000-02-14 PT PT00909165T patent/PT1152750E/pt unknown
- 2000-02-14 NZ NZ513529A patent/NZ513529A/en not_active IP Right Cessation
- 2000-02-14 SI SI200031035T patent/SI1152750T1/sl unknown
- 2000-02-14 DE DE60042151T patent/DE60042151D1/de not_active Expired - Lifetime
- 2000-02-14 HU HU0105364A patent/HUP0105364A3/hu unknown
- 2000-02-14 ES ES00909165T patent/ES2326783T3/es not_active Expired - Lifetime
- 2000-02-15 MY MYPI20000530A patent/MY128362A/en unknown
- 2000-03-13 TW TW089104503A patent/TWI240636B/zh not_active IP Right Cessation
-
2001
- 2001-02-14 ZA ZA200106677A patent/ZA200106677B/en unknown
- 2001-07-23 IL IL144512A patent/IL144512A/en not_active IP Right Cessation
- 2001-08-15 US US09/930,335 patent/US20020061873A1/en not_active Abandoned
- 2001-08-15 NO NO20013964A patent/NO331232B1/no not_active IP Right Cessation
-
2007
- 2007-09-21 US US11/859,077 patent/US8575147B2/en not_active Expired - Fee Related
-
2008
- 2008-07-04 EC EC2008003351A patent/ECSP083351A/es unknown
- 2008-07-07 IL IL192666A patent/IL192666A0/en unknown
-
2009
- 2009-07-31 CL CL2009001682A patent/CL2009001682A1/es unknown
-
2011
- 2011-08-05 AR ARP110102851A patent/AR082579A2/es not_active Application Discontinuation
-
2012
- 2012-01-05 JP JP2012000816A patent/JP2012111763A/ja active Pending
-
2013
- 2013-10-15 US US14/053,661 patent/US8722664B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082579A2 (es) | Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad | |
| ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
| Heuschkel et al. | Microemulsions—modern colloidal carrier for dermal and transdermal drug delivery | |
| BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
| AR027091A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
| CR7654A (es) | Una combinacion de azelatina y esteroides | |
| AR033555A1 (es) | Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos | |
| AR020001A1 (es) | COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO | |
| ECSP056159A (es) | Composición de fármaco conjugado | |
| AR011133A1 (es) | MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA. | |
| CO5640037A2 (es) | Derivados de la quinazolina para el tratamiento del cancer | |
| ATE275393T1 (de) | Feste dispersionen mit nitrataktiven wirkstoffen | |
| DE60004797D1 (de) | Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure | |
| AR086688A2 (es) | Composicion farmaceutica con excipiente liquido modificado, un metodo para producir una composicion farmaceutica y el uso de dicha composicion para preparar un medicamento | |
| AR045783A1 (es) | Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide | |
| DK1280558T3 (da) | Halvfast indgivelsesvehikel og farmaceutiske sammensætninger | |
| UY27341A1 (es) | Formulación farmacéutica de sabor enmascarado y procedimiento para su preparación. | |
| DK1401405T3 (da) | Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed | |
| ES2150404T3 (es) | Composiciones farmaceuticas de tizoxanida y nitozoxanida. | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| AR034142A1 (es) | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion | |
| ES2145114T3 (es) | Combinacion de atovacuona con proguanil para el tratamiento de infecciones protozoarias. | |
| AR029451A1 (es) | Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia | |
| JO2492B1 (en) | A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients | |
| AR025392A1 (es) | Preparado farmaceutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |